1,088 results
Search Results
2. Monoklonale Antikörper für entzündliche, autoimmune und onkologische Hauterkrankungen
3. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
4. Risk of incident venous thromboembolism in patients with atopic dermatitis: systematic analysis of the literature and meta-analysis
5. Isolation of the novel phage SAP71 and its potential use against Staphylococcus aureus in an atopic dermatitis mouse model
6. Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis
7. Association Between Atopic Dermatitis in Pregnant Women and Preterm Births: The Japan Environment and Children’s Study
8. Use of Dupilumab in Pediatric Patients: A Review
9. Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people
10. Phosphodiesterase-4-Inhibitoren in der Dermatologie: Die Rolle in der Behandlung von Hautkrankheiten
11. Efficacy of a Multi-lamellar Emulsion Containing a Synthetic Sphingosine Kinase 1 Activator and Pseudoceramide in Patients with Atopic Dermatitis: A Randomized Controlled Trial
12. Prevention of Atopic Dermatitis in Children: Can It be Done?
13. Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates
14. Management of Moderate-to-Severe Atopic Dermatitis in Adults: A Cross-Sectional Survey of Dermatologists Within the Asia–Pacific Region
15. The biological effects of Rosa rugosa extract on keratinocyte differentiation and enhancement of skin barrier function
16. Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis
17. Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors
18. Quality of Life and Burden of Moderate-to-Severe Atopic Dermatitis in Adult Patients Within the Asia–Pacific Region: A Cross-sectional Survey
19. Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
20. Exploring the Common Pathogenic Mechanisms of Psoriasis and Atopic Dermatitis: The Interaction between SGK1 and TIGIT Signaling Pathways
21. Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study
22. The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis
23. Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia–Pacific Region
24. Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
25. Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies
26. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations
27. Codium fragile extract prevents atopic dermatitis in DNCB-induced mice
28. Disrupting TSLP–TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases
29. The role of the environment in allergic skin disease
30. Innovative Immunotherapy for the Treatment of Atopic Dermatitis: Focus on the European and Latin American Regulatory Frameworks
31. Development of an Atopic Dermatitis Incidence Rate Prediction Model for South Korea Using Air Pollutants Big Data: Comparisons Between Regression and Artificial Neural Network
32. Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
33. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis
34. Topische Therapie bei atopischer Dermatitis, Alopecia areata, Vitiligo: Altbewährtes und Innovationen
35. Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
36. A Systematic Review and Meta-analysis of Mobile Health Applications and Telemonitoring in Atopic Dermatitis Self-Management
37. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
38. Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA
39. Biomarkers in Atopic Dermatitis
40. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
41. Hebammen als Influencer bei der Hautpflege atopisch prädisponierter Neugeborener: Eine Umfrage zu den aktuellen Empfehlungen von Hebammen
42. Sub-acute oral exposure to lowest observed adverse effect level of nivalenol exacerbates atopic dermatitis in mice via direct activation of mitogen-activated protein kinase signal in antigen-presenting cells
43. Fungal Head and Neck Dermatitis: Current Understanding and Management
44. Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome
45. Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics
46. Diagnosis of Allergic Dermatoses in Skin of Color
47. Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
48. Impact of Cosmetics and Cleansers in Atopic Dermatitis—How to Advise Patients
49. Atopic dermatitis: treatment and innovations in immunotherapy
50. Sodium Butyrate Ameliorates Atopic Dermatitis-Induced Inflammation by Inhibiting HDAC3-Mediated STAT1 and NF-κB Pathway
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.